无管路自动胰岛素输注系统与胰岛素泵联合持续葡萄糖监测治疗血糖控制欠佳成人1型糖尿病的疗效与安全性:随机平行组临床试验
这项为期13周的多中心随机对照试验纳入194例血糖控制欠佳的成人1型糖尿病患者,按2:1随机接受无管路自动胰岛素输注(AID)系统或胰岛素泵联合持续葡萄糖监测(CGM)治疗。AID组目标范围内时间(TIR)较对照组高17.5%(95%CI 14.0%–21.1%,P<0.0001),HbA1c降幅更大且低血糖和高血糖时间更少,AID组未发生糖尿病酮症酸中毒或严重低血糖。
要点
- 无管路AID系统较泵联合CGM使TIR提高17.5%(95%CI 14.0%–21.1%,P<0.0001)。
- AID组HbA1c降幅-1.24±0.75%,对照组-0.68±0.93%(P<0.0001)。
- AID组未发生糖尿病酮症酸中毒或严重低血糖。
核心结论
- 在血糖控制欠佳的成人1型糖尿病患者中,使用无管路AID系统较胰岛素泵联合CGM改善了血糖结局,支持将AID系统确立为该人群首选治疗的建议。
研究设计与样本
- 为期13周的多中心、平行组、随机对照试验,在美国和法国进行,纳入18–70岁、HbA1c 7–11%(53–97 mmol/mol)的成人1型糖尿病患者,经2周标准治疗期后按2:1随机分为无管路AID组和泵联合CGM对照组。
- 共随机194例,其中干预组132例、对照组62例。
主要发现
- 试验期间干预组TIR(70–180 mg/dL)较对照组高4.2小时/天(平均差值17.5%[95%CI 14.0%,21.1%];P<0.0001)。
- 干预组HbA1c自基线的降幅大于对照组(均值±标准差 -1.24±0.75%[-13.6±8.2 mmol/mol] vs. -0.68±0.93%[-7.4±10.2 mmol/mol];P<0.0001)。
- 干预组血糖<70 mg/dL的时间显著低于对照组(1.18±0.86% vs. 1.75±1.68%;P=0.005)。
- 干预组血糖>180 mg/dL的时间显著低于对照组(37.6±11.4% vs. 54.5±15.4%;P<0.0001)。
- 所有主要和次要结局均达到,干预组未发生糖尿病酮症酸中毒或严重低血糖。
临床怎么用
- 作者结论指出,无管路AID系统较泵联合CGM改善了成人1型糖尿病患者的血糖结局,并支持将AID系统确立为该人群首选治疗的建议。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the efficacy and safety of the tubeless Omnipod 5 automated insulin delivery (AID) system compared with pump therapy with a continuous glucose monitor (CGM) in adults with type 1 diabetes with suboptimal glycemic outcomes. RESEARCH DESIGN AND METHODS: In this 13-week multicenter, parallel-group, randomized controlled trial performed in the U.S. and France, adults aged 18-70 years with type 1 diabetes and HbA1c 7-11% (53-97 mmol/mol) were randomly assigned (2:1) to intervention (tubeless AID) or control (pump therapy with CGM) following a 2-week standard therapy period. The primary outcome was a treatment group comparison of time in range (TIR) (70-180 mg/dL) during the trial period. RESULTS: A total of 194 participants were randomized, with 132 assigned to the intervention and 62 to the control. TIR during the trial was 4.2h/day higher in the intervention compared with the control group (mean difference 17.5% [95% CI 14.0%, 21.1%]; P < 0.0001). The intervention group had a greater reduction in HbA1c from baseline compared with the control group (mean ± SD -1.24 ± 0.75% [-13.6 ± 8.2 mmol/mol] vs. -0.68 ± 0.93% [-7.4 ± 10.2 mmol/mol], respectively; P < 0.0001), accompanied by a significantly lower time <70 mg/dL (1.18 ± 0.86% vs. 1.75 ± 1.68%; P = 0.005) and >180 mg/dL (37.6 ± 11.4% vs. 54.5 ± 15.4%; P < 0.0001). All primary and secondary outcomes were met. No instances of diabetes-related ketoacidosis or severe hypoglycemia occurred in the intervention group. CONCLUSIONS: Use of the tubeless AID system led to improved glycemic outcomes compared with pump therapy with CGM among adults with type 1 diabetes, underscoring the clinical benefit of AID and bolstering recommendations to establish AID systems as preferred therapy for this population.
引用
- Renard E, Weinstock RS, Aleppo G, et al. Efficacy and Safety of a Tubeless AID System Compared With Pump Therapy With CGM in the Treatment of Type 1 Diabetes in Adults With Suboptimal Glycemia: A Randomized, Parallel-Group Clinical Trial. Diabetes Care. 2024. PMID: 39423118. doi:10.2337/dc24-1550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。